Western consumer health companies are increasingly looking to China as both a growth market and a source of scientific validation. China is one of the world’s fastest-growing markets for infant formula, dietary supplements and complementary medicines. According to 2024 industry data, Australia, the United States, and Germany are the top exporters of health supplements to China, with China remaining Australia’s largest export market.

Against this backdrop, well-designed and well-conducted clinical trials in China will result in high-quality English publications, offering a powerful way to strengthen brand credibility and accelerate commercial success.

Acurit helps Western consumer health companies design and deliver high-quality clinical trials in China that support compliant, evidence-based marketing. Our focus is to generate robust clinical data suitable for publication in peer-reviewed journals, engage respected Chinese key opinion leaders and principal investigators, and build long-term scientific credibility. English-language publications arising from China-based studies can also be leveraged globally, supporting claims substantiation across multiple jurisdictions.

Conducting consumer health clinical trials in China offers significant advantages. Trials can be substantially more cost-effective—industry reports indicate that clinical trials in China can be up to 64% cheaper than in many Western markets—while providing access to a large and diverse participant pool. Studies are conducted in accordance with ICH-GCP and applicable regulatory guidelines, ensuring quality, integrity, and journal acceptability of the data. For brands seeking to differentiate in a crowded category, China-based clinical evidence can be a strategic asset.

Acurit provides end-to-end trial management tailored to the needs of Western sponsors. Working with Chinese local clinical vendors, we support protocol development aligned with product positioning and regulatory strategy, site and investigator selection, ethics submissions, study oversight, and data management.

Acting as your cross-border bridge, we align expectations between Western R&D and commercial teams and Chinese clinical partners, ensuring timelines, budgets, and quality standards are met.

Beyond trial execution, Acurit also supports manuscript development for publication in peer-reviewed journals partnering with Edanz. We work closely with authors—who are trial investigators—and sponsors to translate clinical results into clear, compelling scientific narratives suitable for international audiences. This integrated and end-to-end approach—from study design to publication—maximizes the return on your clinical investment.

We understand the commercial drivers behind consumer health products and the scientific rigor required to substantiate claims. By uniting Western commercial strategy with Chinese clinical execution, Acurit helps bring credible, publishable evidence to life for Western consumer brands.

Why should a Western nutrition company conduct a clinical trial in China?
To publish credible scientific evidence based on trial results that supports ethical and compliant marketing, eventually accelerate commercial success.

English-language publications arising from China-based studies can also be leveraged globally, supporting claims substantiation across multiple jurisdictions.

What is involved in running a nutrition trial in China?
The process includes trial sites selection, regulatory approval, participant recruitment, study conduct from first participant in to last participant out, data collection, statistical analysis, and preparation of the clinical study report.

Who are the key local partners in China?
Specialised nutrition Clinical Research Organisations (CROs), study sites and principal investigators, central laboratories for biosample testing, data management and statistical teams.

Choosing the right local partners is vital.

How does Acurit manage challenges in nutrition clinical trials?
We provide hands-on vendor selection and management, risk mitigation, and problem solving. In one instance, after a stalled trial achieved only 3% enrolment, we replaced the CRO through our extensive professional network in China, expanded hospital sites, and completed enrolment of approximately 200 participants, who were newborn infants, within six months.

What advice would you give a Western nutrition company before they start a trial in China?
Select the right local trial partners, define roles and responsibilities clearly, and co-create the protocol in both English and Chinese to ensure alignment from the start.

What does publishing a nutrition trial involve?
It includes journal selection, manuscript writing, submission, revision, and acceptance in a peer-reviewed journal. A nutrition company can choose to develop it in-house, or work with professional medical writers. When you do so, make sure the medical writers are Certified Medical Publication Professionals by the International Society for Medical Publication Professionals.

How does Acurit support publication?

With our collaborators who are publication experts, we support authors to develop high-quality manuscripts and manage the submission process, ensuring your clinical investment translates into global scientific credibility.

Do you have an example of Acurit’s end-to-end clinical trial and publication support?
Yes. We support sponsors from protocol development through trial conduct to peer-reviewed publication. A representative study was published in the Journal of Nutrition Health and Aging. The manuscript progressed from writing to acceptance in just eight months.

Has Acurit shared insights publicly on nutrition clinical trials in China?
Yes. Our Founder Dr Mao was interviewed by HPA Global Insights in a feature titled “Clinical Research in China – A Strategic Move for Global Nutrition Industry,” sharing practical insights on cross-border nutrition trials. Access the video here.

Page last updated: February 18, 2026